Using the peptide “megapooller” prescribed by HLA class I and II, the research group detected CD8+ and CD4+ T cells specific to SARS-CoV-2 in the blood samples of 70–100% of healing COVID-19 patients. This evidence concerns the gene CD8A and COVID-19.